Eine neue Studie an Mäusen zeigt, dass ein Medikament zur Behandlung überschüssiger Kupferwerte die Wahrscheinlichkeit, dass Kinder an der seltenen Krebserkrankung Neuroblastom leiden, von 10 % auf 50 % verbessern könnte
https://www.unsw.edu.au/newsroom/news/2024/12/why-copper-could-be-the-key-to-treating-a-rare-childhood-cancer?utm_source=reddit&utm_medium=social
3 Comments
Hi r/science – sharing this study led by Associate Professor Orazio Vittorio from our School of Biomedical Sciences and the Children’s Cancer Institute here in Sydney.
Published in Nature Communications, the study may offer hope for children with neuroblastoma who relapse: [Copper chelation redirects neutrophil function to enhance anti-GD2 antibody therapy in neuroblastoma](https://www.nature.com/articles/s41467-024-54689-x)
Neuroblastoma accounts for 15% of childhood cancer deaths.
The study found that the existing drug triethylenetetramine (marketed as Cuprior) can be used to weaken tumours and strengthen the fighting capacity of immune cells, increasing the success rate of a cancer treatment for **high-risk neuroblastoma** from 10% to 50%.
This study was completed with mice; a clinical trial is expected to start next year.
And it’ll be insanely expensive, not covered by insurance. The rich will afford it while those who cannot will die.
Everyone wants a cure for this however we’ve been curing cancers in mice for years. Maybe 1 out of 1,000 “worked on mice” stories turn into successful, completed Phase III human trials. The positive thing you can do is advocate for more funding for faster Phase I, II, and III trials.